Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Elinzanetant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 20/20 | 0.71 |
| ▸ | TACR3 known ✓ | P29371 | 13/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elinzanetant SCHEMBL29372539 | 1.00 | TACR1 (0.71) | TACR1TACR3CYP3A4 | |
| Elinzanetant SCHEMBL3338389 | 1.00 | TACR1 (0.71) | TACR1TACR3CYP3A4 | |
| Elinzanetant SCHEMBL22655398 | 1.00 | TACR1 (0.71) | TACR1TACR3CYP3A4 | |
| Elinzanetant SCHEMBL31181463 | 1.00 | TACR1 (0.71) | TACR1TACR3CYP3A4 | |
| Elinzanetant SCHEMBL336660 | 1.00 | TACR1 (0.71) | TACR1TACR3CYP3A4 | |
| Elinzanetant SCHEMBL337510 | 0.99 | TACR1 (0.70) | TACR1TACR3CYP3A4 | |
| Elinzanetant SCHEMBL9930302 | 0.99 | TACR1 (0.70) | TACR1TACR3CYP3A4 | |
| Elinzanetant SCHEMBL30106837 | 0.99 | TACR1 (0.70) | TACR1TACR3CYP3A4 | |
| SCHEMBL14026952 | 0.98 | TACR1 (0.68) | TACR1TACR3CYP3A4 | |
| SCHEMBL15304572 | 0.96 | TACR1 (0.66) | TACR1TACR3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533358-B1 | Methods of treatment with elinzanetant | BAYER CONSUMER CARE AG (CH) | 2026-01-27 | — | — | US | claimed |
| US-20260014166-A1 | NOVEL USES OF DUAL NK-1 /NK-3 RECEPTOR ANTAGONISTS FOR TREATING SEX-HORMONE DISEASES | KaNDy Therapeutics Limited (GB) | 2026-01-15 | — | — | US | claimed |
| WO-2025242583-A1 | NOVEL FORMULATION COMPRISING ELINZANETANT IN A SOLID DISPERSION | BAYER CONSUMER CARE AG (CH) | 2025-11-27 | — | — | WO | claimed |
| US-20250270330-A1 | TREATMENT OF HEADACHE DISORDERS WITH NK3 MODULATORS | KALLYOPE, INC. | 2025-08-28 | — | — | US | claimed |
| US-12264164-B2 | Method of treatment of symptoms of menopause | KaNDy Therapeutics Limited (GB) | 2025-04-01 | — | — | US | claimed |
| EP-4514351-A1 | TREATMENT OF HEADACHE DISORDERS WITH NK3 MODULATORS | Kallyope, Inc. (US) | 2025-03-05 | — | — | EP | claimed |
| EP-4431512-A1 | NOVEL DUAL NK-1/NK-3 RECEPTOR ANTAGONISTS | Bayer Consumer Care AG (CH) | 2024-09-18 | — | — | EP | claimed |
| US-20230382922-A1 | METHOD OF TREATMENT OF SYMPTOMS OF MENOPAUSE | KaNDy Therapeutics Limited (GB) | 2023-11-30 | — | — | US | claimed |
| EP-3765024-B1 | NOVEL PHARMACEUTICAL FORMULATION COMPRISING DUAL NK-1/NK-3 RECEPTOR ANTAGONISTS. | KANDY THERAPEUTICS LTD (GB) | 2023-11-22 | — | — | EP | claimed |
| WO-2023211779-A1 | TREATMENT OF HEADACHE DISORDERS WITH NK3 MODULATORS | KALLYOPE, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-10774091-B2 | Soft gelatin capsule formulation | KaNDy Therapeutics Limited (GB) | 2020-09-15 | — | — | US | claimed |
| US-20190284205-A1 | NOVEL PHARMACEUTICAL FORMULATION | KaNDy Therapeutics Limited (GB) | 2019-09-19 | — | — | US | claimed |
| US-10195205-B2 | Uses of dual NK1/NK3 receptor antagonists for treating sex-hormone diseases | NERRE THERAPEUTICS LIMITED (GB) | 2019-02-05 | — | — | US | claimed |
| EP-3297631-A1 | DUAL NK-1/NK-3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SEX-HORMONE-DEPENDENT DISEASES | NeRRe Therapeutics Limited (GB) | 2018-03-28 | — | — | EP | claimed |
| US-20160339037-A1 | Novel Uses | KaNDy Therapeutics Limited (GB) | 2016-11-24 | — | — | US | claimed |
| WO-2016184829-A1 | DUAL NK-1/NK-3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SEX-HORMONE-DEPENDENT DISEASES | NERRE THERAPEUTICS LIMITED (GB) | 2016-11-24 | — | — | WO | claimed |
| EP-1928886-B1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXOSMITHKLINE LLC (US) | 2011-04-13 | — | — | EP | claimed |
| US-7919491-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | claimed |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | GLAXOSMITHKLINE LLC (US) | 2010-06-17 | — | — | US | claimed |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2008-10-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774091-B2 | Soft gelatin capsule formulation | COL2A1, GNE, SIRT7 | TACR1 3544/4885TACR3 4572/4885CYP3A4 1312/4885 |
| US-20260014166-A1 | NOVEL USES OF DUAL NK-1 /NK-3 RECEPTOR ANTAGONISTS FOR TREATING SEX-HORMONE DISEASES | KISS1R, GPER1, FSHR | TACR1 65/4885TACR3 191/4885CYP3A4 1878/4885 |
| US-10195205-B2 | Uses of dual NK1/NK3 receptor antagonists for treating sex-hormone diseases | KISS1R, KLKB1, KLK3 | TACR1 11/4885TACR3 35/4885CYP3A4 2058/4885 |
| US-20160339037-A1 | Novel Uses | KLKB1, KLK3, KLK1 | TACR1 20/4885TACR3 22/4885CYP3A4 2836/4885 |
| US-20230382922-A1 | METHOD OF TREATMENT OF SYMPTOMS OF MENOPAUSE | CYP19A1, MTNR1B, SHBG | TACR1 584/4885TACR3 1041/4885CYP3A4 808/4885 |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | SLC6A3, NDUFS5, NDUFB6 | TACR1 1788/4885TACR3 1889/4885CYP3A4 308/4885 |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | CHRNA7, NR3C2, CHRNA6 | TACR1 252/4885TACR3 312/4885CYP3A4 736/4885 |
| US-12533358-B1 | Methods of treatment with elinzanetant | KISS1R, AVPR1B, KLKB1 | TACR1 61/4885TACR3 630/4885CYP3A4 103/4885 |
| US-20190284205-A1 | NOVEL PHARMACEUTICAL FORMULATION | HTR5A, PDE12, PDE4B | TACR1 675/4885TACR3 1902/4885CYP3A4 144/4885 |
| US-12264164-B2 | Method of treatment of symptoms of menopause | CYP19A1, MTNR1B, SHBG | TACR1 584/4885TACR3 1041/4885CYP3A4 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.